Table 1 Baseline characteristics of the study patients
Group 1 | Group 2 | p-value | ||
|---|---|---|---|---|
Subgroup 1A | Subgroup 1B | |||
Age, mean (SD) | 65.5 ± (10.4) | 63.6 ± (7.1) | 72.5 ± (8.1) | 0.005** |
Sex | ||||
Female | 13 (54.2%) | 6 (33.3%) | 5 (35.7%) | 0.267 |
Male | 11 (45.8%) | 12 (66.7%) | 9 (64.3%) | |
Type of DM | ||||
Type 1 | 5 (20.9%) | 4 (22.2%) | 2 (14.3%) | 0.82 |
Type 2 | 19 (79.1%) | 14 (77.8%) | 12 (85.7%) | |
Last known HBA1C, mean (SD) | 7.2 ± (0.8) | 7.5 ± (1.5) | 7.5 ± (1.2) | 0.91 |
Insulin use (%) | 17 (70.8%) | 12 (66.7%) | 8 (57.1%) | 0.89 |
Anti-VEGF treatment Naïve eyes (%) | 14 (58.3%) | 9 (50%) | 9 (64.2%) | 0.71 |
Prior focal laser treatment (%) | 10 (41.6%) | 6 (33.3%) | 7 (50%) | 0.64 |
Prior PRP treatment (%) | 5 (20.8%) | 2 (11.1%) | 0 (0%) | 0.17 |
Baseline logMAR VA, mean (SD) | 0.58 ± (0.29) | 0.65 ± (0.34) | 0.55 ± (0.24) | 0.87 |
Baseline CRT measurement (µm) (SD) | 445.92 ± (126.4) | 537.72 ± (131.7) | 410.87 ± (86.4) | 0.011* |